Fundamental Analysis of VERRICA PHARMACEUTICALS INC(NASDAQ:VRCA) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to VRCA. VRCA was compared to 194 industry peers in the Pharmaceuticals industry. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative. VRCA is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

VRCA had negative earnings in the past year.

VRCA had a negative operating cash flow in the past year.

In the past 5 years VRCA always reported negative net income.

VRCA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of VRCA (-167.14%) is worse than 88.02% of its industry peers.

		Industry Rank	Sector Rank
ROA	-167.14%
ROE	N/A
ROIC	N/A

ROA(3y)-60.22%

ROA(5y)-55.89%

ROE(3y)-169.25%

ROE(5y)-136.11%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VRCA has a better Gross Margin (84.03%) than 91.15% of its industry peers.

The Profit Margin and Operating Margin are not available for VRCA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	84.03%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.

VRCA has more shares outstanding than it did 1 year ago.

VRCA has more shares outstanding than it did 5 years ago.

VRCA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -10.87, we must say that VRCA is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -10.87, VRCA is doing worse than 77.08% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-10.87

ROIC/WACCN/A

WACC10.71%

2.3 Liquidity

A Current Ratio of 2.36 indicates that VRCA has no problem at all paying its short term obligations.

VRCA's Current ratio of 2.36 is in line compared to the rest of the industry. VRCA outperforms 41.67% of its industry peers.

VRCA has a Quick Ratio of 2.23. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.

VRCA's Quick ratio of 2.23 is in line compared to the rest of the industry. VRCA outperforms 46.35% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.36
Quick Ratio	2.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VRCA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.03%.

Looking at the last year, VRCA shows a very strong growth in Revenue. The Revenue has grown by 186.92%.

EPS 1Y (TTM)-71.03%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%9.26%

Revenue 1Y (TTM)186.92%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-161.06%

3.2 Future

The Earnings Per Share is expected to grow by 30.62% on average over the next years. This is a very strong growth

VRCA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 143.70% yearly.

EPS Next Y-7.29%

EPS Next 2Y23.34%

EPS Next 3Y20.26%

EPS Next 5Y30.62%

Revenue Next Year183.23%

Revenue Next 2Y152.31%

Revenue Next 3Y136.11%

Revenue Next 5Y143.7%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VRCA's earnings are expected to grow with 20.26% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.34%

EPS Next 3Y20.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VRCA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (11/22/2024, 8:12:06 PM)

After market: 1.01 +0.02 (+1.56%)

0.9945

+0 (+0.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap45.35M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-167.14%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	84.03%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.27

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.36
Quick Ratio	2.23
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-71.03%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-7.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)186.92%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VERRICA PHARMACEUTICALS INC (VRCA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens